CR20220313A - Formulación pediátrica de liberación inmediata del abridor de canales de potasio ezogabina - Google Patents

Formulación pediátrica de liberación inmediata del abridor de canales de potasio ezogabina

Info

Publication number
CR20220313A
CR20220313A CR20220313A CR20220313A CR20220313A CR 20220313 A CR20220313 A CR 20220313A CR 20220313 A CR20220313 A CR 20220313A CR 20220313 A CR20220313 A CR 20220313A CR 20220313 A CR20220313 A CR 20220313A
Authority
CR
Costa Rica
Prior art keywords
immediate release
ezogabine
pediatric formulation
opener
potassium
Prior art date
Application number
CR20220313A
Other languages
English (en)
Inventor
Jean-Jacques Alexandre Cadieux
Matthew David Tandy
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of CR20220313A publication Critical patent/CR20220313A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se divulga en la presente formulaciones farmacéuticas orales de liberación inmediata que comprende una cantidad terapéuticamente efectiva de ezogabina y uno o más excipientes farmacéuticamente aceptables para uso en el tratamiento de la epilepsia y/o del trastorno de crisis epilépticas en un mamífero, preferentemente un humano, más preferentemente un niño. También se divulgan métodos para usar y hacer las formulaciones farmacéuticas orales de liberación inmediata.
CR20220313A 2019-12-02 2020-12-02 Formulación pediátrica de liberación inmediata del abridor de canales de potasio ezogabina CR20220313A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962942579P 2019-12-02 2019-12-02
PCT/US2020/062918 WO2021113381A1 (en) 2019-12-02 2020-12-02 Pediatric immediate-release formulation of the potassium channel opener ezogabine

Publications (1)

Publication Number Publication Date
CR20220313A true CR20220313A (es) 2022-10-31

Family

ID=74181279

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220313A CR20220313A (es) 2019-12-02 2020-12-02 Formulación pediátrica de liberación inmediata del abridor de canales de potasio ezogabina

Country Status (15)

Country Link
US (1) US20210169839A1 (es)
EP (1) EP4069201A1 (es)
JP (1) JP2023504154A (es)
KR (1) KR20220108116A (es)
CN (1) CN114760990A (es)
AU (1) AU2020395158A1 (es)
BR (1) BR112022010458A2 (es)
CA (1) CA3162907A1 (es)
CL (1) CL2022001426A1 (es)
CO (1) CO2022007345A2 (es)
CR (1) CR20220313A (es)
IL (1) IL293352A (es)
MX (1) MX2022006472A (es)
PE (1) PE20221396A1 (es)
WO (1) WO2021113381A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4200259A1 (de) 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
WO2010009433A1 (en) * 2008-07-18 2010-01-21 Valeant Pharmaceuticals International Modified release formulation and methods of use
DE102009013612A1 (de) * 2009-03-17 2010-09-23 Ratiopharm Gmbh Retigabin-Tabletten, bevorzugt mit modifizierter Freisetzung
DE102009013613A1 (de) * 2009-03-17 2010-09-23 Ratiopharm Gmbh Trockenverarbeitung von Retigabin
WO2011039369A2 (en) * 2009-10-02 2011-04-07 Medichem S.A. Amorphous forms of a 2-amino-4-(4-fluorobenzylamino)phenylcarbamate derivative
KR20120118012A (ko) * 2010-01-20 2012-10-25 글락소 그룹 리미티드 신규의 레티가빈 조성물
US20130267590A1 (en) * 2011-09-13 2013-10-10 Dr. Reddy's Laboratories Limited Retigabine compositions

Also Published As

Publication number Publication date
PE20221396A1 (es) 2022-09-14
EP4069201A1 (en) 2022-10-12
US20210169839A1 (en) 2021-06-10
CL2022001426A1 (es) 2023-03-24
CA3162907A1 (en) 2021-06-10
CN114760990A (zh) 2022-07-15
CO2022007345A2 (es) 2022-06-10
IL293352A (en) 2022-07-01
MX2022006472A (es) 2022-09-09
BR112022010458A2 (pt) 2022-09-06
WO2021113381A1 (en) 2021-06-10
KR20220108116A (ko) 2022-08-02
JP2023504154A (ja) 2023-02-01
AU2020395158A1 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
ECSP088394A (es) Formulación de cápsula de pirfenidona y excipientes farmacéuticamente aceptables
CO2019000945A2 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
CO2019000943A2 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
CO2019000941A2 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
CO2017007003A2 (es) Formulaciones de sunitinib y métodos para uso de las mismas en el tratamiento de trastornos oculares
BR112019001923A2 (pt) moduladores de nmda de espiro-lactama e métodos de sua utilização
AR058679A1 (es) Preparacion farmaceutica que contiene meloxicam
MX2022005465A (es) Metodos de tratamiento con modulador de miosina.
PE20221280A1 (es) Formulaciones de moduladores de canales ionicos y metodos de preparacion y uso de moduladores de canales ionicos
PE20191407A1 (es) Uso de gaboxadol en el tratamiento de tinnitus
CO6270217A2 (es) Formulaciones galenicas de alisquireno y valsartan
CL2007002875A1 (es) Composicion farmaceutica recubierta por una pelicula que comprende capecitabina y al menos un disgregante, util en el tratamiento del cancer para pacientes que tienen dificultad para tragar las formas de dosificacion solidas orales.
CL2011002766A1 (es) Compuestos derivados de carboxamida, inhibidores de calpaina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas, alzahimer, dolor, entre otras.
AR022589A1 (es) UNA CÁPSULA QUE COMPRENDE UNA COMPOSICIoN FARMACÉUTICA ESPONTÁNEAMENTE DISPERSABLE PARA LA ADMINISTRACIoN ORAL, UNA COMPOSICIoN FARMACÉUTICA ESPONTÁNEAMENTE DISPERSABLE PARA LA ADMINISTRACIoN ORAL Y EL USO PARA LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DEL CÁNCER
CO2023013050A2 (es) Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas
UY35091A (es) Formulaciones de liberacion modificada para oprozomib
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
AR115913A1 (es) Formas de dosificación oral biodisponibles, uso, métodos
CY1125075T1 (el) Εκχυλισμα salvia haenkei σαν δραστικος παραγοντας στις διαδικασιες επανεπιθηλιωσης και επουλωσης ιστων
MX2023012741A (es) Formulaciones farmaceuticas liquidas concentradas de furosemida y metodos para administrar las mismas.
MX2020000164A (es) Formulaciones de isotretinoína para la mucosa oral y métodos para usar las mismas.
CR20220313A (es) Formulación pediátrica de liberación inmediata del abridor de canales de potasio ezogabina
CL2020001426A1 (es) Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo.
AR074246A1 (es) Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno
UY37413A (es) Formulaciones de liberación inmediata de oprozomib